Target of Rapamycin (TOR), a giant protein kinase expressed by all eucaryotic cells, controls cell size in response to nutrient signals. In metazoans, cell and organismal growth is controlled by nutrients and the insulin/insulin-like growth factor (IGF) system, and the understanding of how these inputs coordinately regulate TOR signaling has advanced greatly in the past 5 years. In single-cell eucaryotes and Caenorhabditis elegans, TOR is a dominant regulator of overall mRNA translation, whereas in higher metazoans, TOR controls the expression of a smaller fraction of mRNAs that is especially important to cell growth. TOR signals through two physically distinct multiprotein complexes, and the control of cell growth is mediated primarily by TOR complex 1 (TORC1), which contains the polypeptides raptor and LST8. Raptor is the substrate binding element of TORC1, and the ability of raptor to properly present substrates, such as the translational regulators 4E-BP and p70 S6 kinase, to the TOR catalytic domain is essential for their TOR-catalysed phosphorylation, and is inhibited by the Rapamycin/FKBP-12 complex. The dominant proximal regulator of TORC1 signaling and kinase activity is the ras-like small GTPase Rheb. Rheb binds directly to the mTOR catalytic domain, and Rheb-GTP enables TORC1 to attain an active configuration. Insulin/ IGF enhances Rheb GTP charging through the ability of activated Akt to inhibit the Rheb-GTPase-activating function of the tuberous sclerosis heterodimer (TSC1/ TSC2). Conversely, energy depletion reduces Rheb-GTP charging through the ability of the adenosine monophosphate-activated protein kinase to phosphorylate TSC2 and stimulate its Rheb-GTPase activating function, as well as by HIFa-mediated transcriptional responses that act upstream of the TSC1/2 complex. Amino-acid depletion inhibits TORC1 acting predominantly downstream of the TSC complex, by interfering with the ability of Rheb to bind to mTOR. The components of the insulin/ IGF pathway to TORC1 are now well established, whereas the elements mediating the more ancient and functionally dominant input of amino acids remain largely unknown. Oncogene (2006 Oncogene ( ) 25, 6361-6372. doi:10.1038 Keywords: TOR; Rheb; TSC; S6K; raptor; leucine
Discovery of TOR, the target of Rapamycin
Rapamycin is a natural product of Streptomyces hygroscopicus identified in the 1970s as an antifungal agent (Vezina et al., 1975) , and shown to have antitumor activity. Development of the drug for these indications was interrupted by the discovery of its immunosuppressant activity, but resumed with the latter as the primary clinical indication (Sehgal, 2003) . Rapamycin and the immunosuppressant drugs cyclosporine and FK506 operate through a novel mechanism of action; these agents interact with the targets responsible for their pharmacologic actions only when complexed with abundant cellular proteins, collectively called immunophilins (Schreiber, 1991; Dumont and Su, 1995; Abraham and Wiederrecht, 1996) . Rapamycin and FK506, which are structurally related, share the same immunophilin, a 12 kDa polypeptide with peptidyl-prolyl isomerase activity first identified as an FK506-binding protein. Both drugs, through their shared structural domain, bind to a common single site on FKBP12, but the two drug-FKBP12 complexes exhibit entirely distinct effects on T-cell function, and interact with completely different targets. The finding that deletion of both alleles of the Saccharomyces cerevisiae FKBP12 homolog prevents Rapamycin inhibition of yeast growth indicated that Rapamycin utilized a similar mechanism of action in yeast as in T cells (Heitman et al., 1991; Koltin et al., 1991) . The identification of Rapamycinresistant S. cerevisiae mutants whose resistance could be transferred as a dominant trait enabled the rapid isolation of the mutant gene, the parental wild-type gene and a second, closely related gene. The two wildtype genes were named TOR (target of Rapamycin)-1 and TOR2 and encoded polypeptides of nearly 300 kDa, each containing in its carboxy-terminal region a kinase catalytic domain whose amino acid sequence is more similar to those of the phosphatidyl inositol lipid kinases than to that canonical protein (Tyr/Ser/Thr) kinases (Cafferkey et al., 1993; Kunz et al., 1993) . Nevertheless, TOR1/2 are the founding members of the phosphatidyl inositol kinase-like protein kinase (PIKK) subfamily of protein (Ser/Thr) kinases, which includes ATM, ATR, DNA-PK and others (Abraham, 2004) . The following year, affinity purification with drug-immunophilin complexes (Brown et al., 1994; Sabatini et al., 1994; Sabers et al., 1995) and, independently, two-hybrid screening with FKBP12/Rapamycin in a Rapamycinresistant yeast strain (Chiu et al., 1994) each retrieved the mammalian targets of Rapamycin, which proved to be TOR polypeptides. The latter were shown to bind directly to the Rapamycin/FKBP12 complex through a conserved, independently folding domain (the FKBP12/ Rapamycin Binding (FRB) domain) situated slightly amino-terminal to the TOR catalytic domain Choi et al., 1996) . The Rapamycin-resistant yeast TOR2 mutant contained a single Ser to Arg mutation in this domain that abolished binding to the Rapamycin/FKBP12 complex.
Rapamycin and the p70 S6 kinase
Before the discovery of TOR, we were introduced to Rapamycin by Barbara Bierer, who was investigating the biochemical mechanism of action of these immunosuppressant agents in mammalian cells (Bierer et al., 1991) . Our lab was trying to understand the mechanisms by which insulin stimulated protein (ser/thr) phosphorylation; we had recently purified (Price et al., 1989) and molecularly cloned (Banerjee et al., 1990; Grove et al., 1991) a 70 kDa rat liver protein kinase responsible for the phosphorylation of the 40S ribosomal polypeptide S6. This kinase is activated in vivo during liver regeneration (Nemenoff et al., 1988) and by injection of the protein synthesis inhibitor cyclohexamide (Price et al., 1989) , and is identical to the S6 kinase (S6K) activated by insulin in rat hepatoma cells . Maller (1985, 1986 ) had previously purified the major insulin-activated S6K from Xenopus oocytes, and isolated cDNAs encoding the mammalian counterparts, named Rsks (Jones et al., 1988) , which are structurally distinct from the p70 S6K. Nevertheless, the Rsks are also activated by insulin in mammalian cells (Chen and Blenis, 1990 ) and catalyse extensive phosphorylation of 40S-S6 in vitro. Our goal was to understand how insulin activated each of these S6Ks. In collaboration with Bierer, we observed that Rapamycin inhibited by >98% the activity of endogenous and recombinant p70 S6K as well as the phosphorylation of S6 within minutes in all cells examined, with an IC 50 near 2 nM; by contrast, the activity of the Rsks was entirely unaffected (Price et al., 1992) . This finding identified p70 kinase as the dominant S6K in mammalian cells. Moreover, inasmuch as the p70 S6K was unaffected by direct addition of an FKBP12/Rapamycin complex, we inferred that Rapamycin acted on a target situated upstream of p70 S6K that was not required for insulin signaling to Rsk; the latter is mediated by the Ras/mitogen-activated protein kinase (MAPK) pathway (Sturgill et al., 1988; Avruch et al., 1994) , which makes little or no contribution to the regulation of the a-isoform of p70 S6K1.
The identification of relatively selective inhibitors of the Type 1 phosphatidyl inositol kinases (e.g., wortmannin (at o0.1 mM) and Ly294002) enabled the demonstration that these phospholipid kinases are required for insulin signaling to the p70 S6K (as well as nearly all of insulin's metabolic targets) (Cheatham et al., 1994; Chung et al., 1994) . In addition, the finding that a Rapamycin-resistant mTOR FRB (Ser2035Ile or Thr) mutant rescued coexpressed p70 S6K from inhibition by Rapamycin certified mTOR as the Rapamycinsensitive target upstream of the p70 S6K Hara et al., 1997) . Thus, the question arose as to how the input provided by the Type 1A phosphatidyl inositol kinase related to that provided by mTOR. Overexpression of PI-3 kinase itself (Weng et al., 1995a) , or Akt (Burgering and Coffer, 1995) , a PI-3 kinase target, can each strongly and selectively activate coexpressed p70 S6K in a Rapamycin-sensitive manner, indicating either that mTOR was situated downstream of PI-3 kinase/Akt, or that mTOR contributed to S6K activation in a necessary but independent way. A structure/function analysis of the p70 S6K suggested that the input from PI-3K was, at least in part, independent of mTOR (Cheatham et al., 1995; Weng et al., 1995b) ; deletion of a short segment from the S6K non-catalytic amino-terminal flank reduces S6K activity by >95%. The low activity of the amino-terminally deleted S6K can be partially restored by additional deletion of the S6K carboxy-terminal non-catalytic flank, a segment shown previously to contain a pseudosubstrate autoinihibitory domain . Notably, the doubly deleted kinase, although activated by insulin and inhibited by wortmannin, is rendered entirely resistant to inhibition by Rapamycin. We speculated that one explanation for this phenotype, among the several available, was that the deletion of the S6K amino-terminal segment might eliminate a necessary activating input, perhaps the input inhibited by Rapamycin. The discovery and elucidation of the function of raptor see below) established that this was in fact the explanation for the Rapamycin insensitivity of the amino-terminally deleted S6K mutants.
Amino-acid regulation of mTOR signaling
The dispensability of the Rapamycin-sensitive input for insulin activation of the doubly deleted S6K mutant suggested the possibility that the Rapamycin-sensitive input, that is, mTOR, might fundamentally subserve a signal separate from insulin. This seemed plausible inasmuch as TOR is phylogenetically older than both the insulin receptor and Type 1A PI-3 kinases. Barbet et al. (1996) showed that the response of S. cerevisiae to Rapamycin or to depletion of both TOR1 and TOR2 was a profound inhibition of overall mRNA translation, and a phenotype characteristic of starved cells entering stationary phase (G0), behavior that suggested that the S. cerevisiae TORs are part of a novel signaling pathway controlling G1 progression in response to nutrient availability. In an effort to determine whether TOR in mammalian cells participates in signaling nutrient availability independent of regulation by insulin, we examined the response of the Rapamycin-sensitive targets and the insulin signaling pathway to the withdrawal of extracellular amino acids (Hara et al., 1998) . This maneuver resulted in a progressive decline in the basal and insulin-stimulated activity of S6K and in the phosphorylation of 4E-BP to essentially undetectable levels after 90-120 min. When conventional medium was replaced by medium lacking single amino acids, leucine withdrawal was observed to cause nearly as profound an inhibition of S6K/4E-BP as removal of all amino acids, and the inhibition caused by arginine withdrawal was almost as severe. In contrast, amino-acid withdrawal did not affect the insulin-stimulated tyrosine phosphorylation of the insulin receptor and IRS proteins, the activity of PI-3 kinase recovered in an anti-TyrP immunoprecipitate or the activity of MAPK and recombinant Akt. Readdition of amino acids restored S6K/4E-BP within 30 min however, the addition of leucine or arginine, singly or together, had little impact. Full responsiveness of S6K to insulin required only 10-20% of the usual level of amino acids; however, raising the level of medium amino acids further resulted in a progressive increase in S6K activity, such that at 2 Â the usual amino-acid level, S6K activity equaled that elicited by a maximal dose of insulin and was not further stimulated by addition of insulin. The S6K activated in response to excess amino acids exhibited a pattern of site-specific phosphorylation indistinguishable from S6K activated by insulin. Evidence that amino-acid-stimulated S6K activity required mTOR was its inhibition by Rapamycin; moreover, the doubly deleted, Rapamycin-resistant S6K mutant proved to be comparably insensitive to inhibition by amino-acid withdrawal. The shared insensitivity of the doubly deleted S6K mutant to Rapamycin and to amino-acid withdrawal indicated that these perturbations acted on S6K (and presumably 4E-BP) through a common effector, most likely mTOR itself. The ability of amino acids to promote mTOR signaling to S6K/4E-BP independently of activation of PI-3 kinase and Akt pointed to the existence of an amino-acid/leucine-responsive signaling pathway independent of the insulin signaling pathway. Both pathways converge on mTOR; however, the input from the amino-acid pathway is dominant, inasmuch as activation by amino acids does not require a concomitant insulin signal, at least in short-term experiments in cell culture, whereas the insulin signal is ineffective in the absence of an amino-acid signal. Using similar approaches, cellular energy/ATP depletion (Dennis et al., 2001 ) (through the adenosine monophosphateactivated protein kinase (AMPK); Bolster et al., 2002; Kimura et al., 2003) and hypoxia (Arsham et al., 2003; Brugarolas et al., 2003 Brugarolas et al., , 2004 have been shown to inhibit insulin activation of wild-type S6K, whereas the doubly deleted S6K mutant is resistant to inhibition by these perturbations, pointing to the ability of these inputs to interfere with the Rapamycin-sensitive component of mTOR signaling. mTOR kinase activity and the function of raptor Brunn et al (1997) were first to show that mTOR could directly phosphorylate 4E-BP in vitro, at several of the multiple Ser/Thr-Pro motifs whose phosphorylation is regulated in vivo by insulin or Rapamycin. Subsequent work demonstrated that mTOR also acts directly in p70 S6K activation. The latter requires multiple phosphorylations in several domains at Ser/Thr situated in diverse amino-acid sequence contexts. The phosphorylation of a cluster of Ser/Thr-Pro sites in an autoinhibitory segment of the carboxy-terminal tail does not alter activity per se (Cheatham et al., 1995; Weng et al., 1995b) , but facilitates access to Thr389 (in the 502 amino-acid S6K1 isoform, corresponding to Thr412 in the 525 amino-acid isoform), which is situated carboxy-terminal to the canonical catalytic domain in the hydrophobic motif FXXFTY (Pearson et al., 1995) . Phosphorylation of Thr389/412 is partially activating per se (Isotani et al., 1999) , but also creates a binding site for phosphoinositide-dependent protein kinase (PDK)-1 (Balendran et al., 1999; Biondi et al., 2001) , which then phosphorylates Ser229/252 in the activation loop of the catalytic domain (Alessi et al., 1998; Pullen et al., 1998) . The simultaneous phosphorylation of both sites activates S6K in a strongly synergistic, almost multiplicative manner (Alessi et al., 1998) , such that elimination of either phosphorylation effectively deactivates the kinase . The phosphorylation at Thr389/412 tracks most closely with S6K1 activity in vivo, and is the site most rapidly dephosphorylated after addition of Rapamycin or Wortmannin, followed closely by the Ser/Thr-Pro sites in the non-catalytic carboxy-terminal tail . Burnett et al. (1998) were first to show that immunoprecipitated mTOR can phosphorylate Thr389/ 412 on a prokaryotic carboxy-terminal fragment of S6K1. The ability of mTOR to phosphorylate Ser/Thr residues situated in such radically different sequence contexts was unexpected and remains exceptional. Nevertheless, Isotani et al. (1999) confirmed the ability of mTOR to directly phosphorylate S6K at Thr389/412 as well as at several Ser/Thr-Pro sites in the carboxyterminal tail and partially activate full-length p70 S6K. Moreover, if S6K, inhibited in vivo (by >98%) by treatment with Rapamycin, is phosphorylated in vitro by mTOR followed by PDK1, S6K activity is restored fully to levels observed when S6K is extracted from serumreplete cells. Taken together, these data strongly support mTOR as a kinase acting directly on both 4E-BP and p70 S6K in vivo.
In addition to mTOR's apparent tolerance of divergent phosphorylation site sequence contexts, Isotani et al. (1999) noted another surprising feature of mTOR kinase activity assayed in vitro; washing the mTOR immunoprecipitate with mild non-ionic detergents (e.g. NP-40 or TritonX100) largely eliminated its ability to phosphorylate 4E-BP, while apparently increasing mTOR autophosphorylation. Conversely, mTOR kinase activity was unaffected by high salt washes. Thus, Hara et al. (2002) partially purified the mTOR kinase activity by several conventional steps compatible with retention of 4E-BP kinase activity, followed by immunoaffinity purification using an mTOR monoclonal antibody. This yielded mTOR together with nearly stoichiometric amounts of 150 and 36 kDa polypeptides. The 150 kDa polypeptide, named raptor, was selectively removed by washing the mTOR immunoprecipitate (IP) with NP-40. Raptor is a 1335-amino-acid non-catalytic protein that contains several novel, conserved segments in its amino-terminal half; in its carboxy-terminal third are seven consecutive WD domain repeats, presumably in a b-propellor structure like the b-subunit of the heterotrimeric Gproteins Kim et al., 2002) . The 36 kDa polypeptide, named GbetaL (Kim et al., 2003) or mLST8, is composed entirely of seven WD domain repeats. An identical complex was isolated by Kim et al. (2002) by immunoprecipitation of mTOR after first treating 293T cells with a dithiothreitol-cleavable cross linker, dithiobis(succinimidylpropionate). Independently, Loewith et al. (2002) immunopurified epitopetagged TOR1 and TOR2 from S. cerevisiae and identified two distinct complexes; KOG1 (homologous to raptor) and LST8 were retrieved with TOR1, whereas LST8 and three different polypeptides (AVO1, 2 and 3) were recovered with TOR2. These workers demonstrated that only the complexes bearing KOG1/raptor were capable of binding to an FKBP12-Rapamycin complex, indicating that the Rapamycin-sensitive actions of TOR are mediated exclusively by the raptorcontaining complexes.
LST8 binds to the mTOR catalytic domain (Kim et al., 2003) ; coexpression with mTOR results in a threeto fivefold, detergent-insensitive increase in TOR complex 1 kinase activity assayed in vitro. Nevertheless, LST8 overexpression does not promote S6K/4E-BP phosphorylation in vivo in serum-or leucine-deprived cells. We have observed no regulation of the LST8/ mTOR interaction in response to various stimuli known to regulate TOR signaling. In S. cerevisae, LST8 is known to be required for 'retrograde' signaling, a transcriptional response elicited in yeast mutants deficient in mitochondrial activity (Butow and Avadhani, 2004) . Whereas this may reflect LST8's necessary role in TOR complex 1 signaling, it has been argued by Butow and co-workers (Giannattasio et al., 2005) that LST8 contributes another, TOR-independent function to the retrograde response .
The importance of raptor for mTOR signaling in higher eucaryotes was shown by the ability of raptor short interfering RNA (siRNA) to inhibit leucinedependent S6K(Thr389) phosphorylation and the leucine-dependent increase in 293T cell size to an extent similar to that caused by mTOR siRNA (Kim et al., 2002) . Moreover, in Caenorhabditis elegans, feeding raptor-directed RNAi recapitulated nearly all of the multiple phenotypes exhibited by CeTOR-deficient worms, whether caused by mutation or by feeding CeTOR-directed RNAi Long et al., 2002) .
The biochemical basis for raptor's biologic functions derives in large part from the raptor's ability to bind both mTOR and the Rapamycin-sensitive mTOR substrates, 4E-BP and p70 S6K, in a manner that enables phosphorylation of the latter by the mTOR catalytic domain. Coexpression of raptor with mTOR markedly increases the 4E-BP and S6K kinase activity of the mTOR IP, assayed in vitro; this activity is diminished progressively by washing the mTOR IP at increasing concentrations of a detergent such as 3-[(3-cholamidopropyl) dimethylammonio]-1-propane sulfonic acid, to an extent that parallels the removal of raptor . Thus, raptor enhancement of the mTOR kinase activity requires the continued association of raptor with mTOR. Raptor binds selectively to 4E-BP and S6K (but not to a variety of mTORirrelevant polypeptides, e.g., PDK1, ERK1, etc.) in a detergent-insensitive manner, binding preferentially to the hypophosphorylated forms of 4E-BP, as shown by replacement of the 4E-BP Ser/Thr phosphorylation sites with either Ala or Glu residues. The binding of 4E-BP to raptor does not interfere with the 4E-BP/eIF-4E interaction. A short sequence called the TOR signaling (TOS) motif, F/Ac/f/Ac/f (where Ac is D/E and f is L/I/M), located at the 4E-BP carboxy-terminus and in the S6K amino-terminal non-catalytic flank (Schalm and Blenis, 2002) , is necessary for the association of these polypeptides to raptor (Beugnet et al., 2003; Choi et al., 2003; Nojima et al., 2003; Schalm et al., 2003) ; mutation of this domain eliminates binding to raptor and the ability of 4E-BP to be phosphorylated in vivo. The S6K TOS motif proves to be the element whose deletion was previously shown to inhibit S6K activity (which is due to the failure to phosphorylate Thr389), as well as render S6K insensitive to inhibition to both Rapamycin and amino-acid withdrawal (Cheatham et al., 1995; Weng et al., 1995b) . Deletion of the S6K carboxy-terminal tail restores access to Thr389 , but the deletion of the TOS motif eliminates S6K binding to raptor and thus its ability to be phosphorylated by TOR complex 1 (Nojima et al., 2003; Ali and Sabatini, 2005) . Interestingly, Ali and Sabatini (2005) presented evidence that the persisting, Rapamycin-independent phosphorylation of Thr389 on the doubly deleted S6K is catalysed by TOR complex 2.
Thus, the susceptibility of 4E-BP and S6K to regulation by Rapamycin and amino-acid sufficiency requires, at a minimum, that these substrates be bound to raptor. Several groups have observed that Rapamycin inhibits the binding of raptor to TOR, both in vivo and in vitro (Kim et al., 2002; Oshiro et al., 2004) ; thus, the inhibitory action of Rapamycin on TOR signaling is likely due to the ability of the Rapamycin/FKBP12 complex to interfere with the proper interaction between raptor and mTOR, rather than or in addition to a more direct inhibition of mTOR catalytic activity. Nevertheless, both in vitro effects require much higher concentrations of the Rapamycin-FKBP12 complex than is required for inhibition of mTOR signaling in vivo, so that the dominant mechanism of Rapamycin/ FKBP12 inhibition of TOR complex 1 remains to be defined. The possibility that raptor plays an active role in amino-acid regulation of substrate phosphorylation by TOR complex 1 is suggested by the finding of Kim et al. (2002) that leucine withdrawal appears to increase the amount of raptor recovered with mTOR, both in the presence and absence of Rapamycin. The mechanism by which leucine regulates the interaction between mTOR and raptor, and its functional significance are unknown.
Insulin and energy sufficiency regulate mTOR kinase signaling by controlling the TSC GTPase activator function toward the Rheb GTPase Several Drosophila laboratories established classical genetic screens to uncover genes that influence cell and organismal size; through the 1990s, such screens had yielded predominantly the known elements of the insulin/insulin-like growth factor (IGF)-1R signaling pathway, for example, the Dros IR/IGF-1 receptor (IGF-1R) homolog, chico, Akt, PI-3 kinase catalytic subunit and PTEN (reviewed by Oldham and Hafen (2003) ). In 2001, three groups identified the genes encoding Drosophila homologs of tuberous sclerosis 1(TSC1)/Hamartin and TSC2/Tuberin, previously known to function as an obligate heterodimer, as negative regulators of cell size (Gao and Pan, 2001; Potter et al., 2001; Tapon et al., 2001) . Mutations in either gene in humans are responsible for the syndrome of tuberous sclerosis (Kwiatkowski, 2003) . The epistatic relationships placed the TSC complex downstream of Akt and upstream of S6K, an arrangement rapidly confirmed by biochemical studies, both in Drosophila and in mammalian cells (Gao et al., 2002; Inoki et al., 2002; Kwiatkowski et al., 2002; Manning et al., 2002; Radimerski et al., 2002; Tee et al., 2002) . The upregulation of S6K activity caused by loss of TSC function is inhibitable by Rapamycin, pointing to an action upstream of TOR. The TSC1/TSC2 polypeptides are structurally non-descript, save for the presence of a GTPase-activating (GAP) domain in the carboxyterminal third of TSC2. In 2003, additional Drosophila screens identified the homolog of the small GTPase Rheb as a positive regulator of cell growth Stocker et al., 2003) , and biochemical studies rapidly identified Rheb as the preferred substrate of the TSC2 GAP activity (Castro et al., 2003; Zhang et al., 2003) . Thus, the genetic evidence indicates that the ability of the TSC complex to inhibit TOR signaling is entirely the result of its ability to deactivate Rheb, which is achieved through its action as a Rheb GTPase activator. Whether the TSC complex has additional biologic functions independent of its ability to deactivate Rheb remains an open question. Many recent reviews of these outstanding discoveries are available (e.g., Oldham and Hafen, 2003; Avruch et al., 2005) .
It is now well established that TSC2 is a key target of regulation by many of the upstream inputs shown previously to regulate TOR and/or S6K activity. Thus insulin, via Akt, directly phosphorylates several sites on TSC2, concomitant with a decrease in the inhibitory activity of TSC on S6K activity (Dan et al., 2002; Inoki et al., 2002; Manning et al., 2002) . The extent to which this reflects dissociation of the TSC1/TSC2 complex, accelerated degradation of the complex or altered catalytic efficacy is uncertain. The MAPK (Ma et al., 2005) and Rsk (Roux et al., 2004) each also phosphorylate TSC2 at distinct sites with a resultant diminution in TSC GAP activity. The AMPK phosphorylates TSC2 in vitro and in vivo at sites that cause an increase in TSC GAP activity, thereby decreasing fractional Rheb-GTP charging, providing the major mechanism for the acute inhibition of TOR complex 1 signaling by ATP depletion (Inoki et al., 2003b) . In addition, hypoxiainducible factor (HIF)-a-directed transcription of the REDD1/2 polypeptides (also called RTP1801/801L (Corradetti et al., 2005) or, in Drosophila, Scylla and Charybdis ), non-catalytic inhibitors of mTOR signaling that act upstream of TSC by undefined mechanisms, provides a second, more delayed mechanism for hypoxic suppression of mTOR signaling (Sofer et al., 2005) . Some data indicate that the direct phosphorylation of TSC2 by Akt is dispensable for physiologic regulation of TSC activity, and that Akt acts indirectly (Dong and Pan, 2004) , perhaps by upregulating cellular ATP production and thereby downregulating the AMPK (Hahn-Windgassen et al., 2005) . Whatever the precise mechanism by which these upstream inputs act, their impact is greatly attenuated in TSC null cells, wherein Rheb GTP charging remains fixed at >95%; consequently, S6K is constitutively active and unaffected by insulin or phorbol esters (a strong activator of the MAPK pathway), inhibition of PI-3 kinase or by 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR), an activator of AMPK (Smith et al., 2005) . In contrast, amino-acid withdrawal remains fully effective in inhibiting S6K in a TSC null background, indicating that amino-acid regulation is exerted predominantly at a site beyond the TSC complex (Smith et al., 2005; Roccio et al., 2006) .
Rheb regulation of mTOR signaling
Given the strong genetic (Patel et al., 2003; Saucedo et al., 2003; Stocker et al., 2003) and biochemical (Castro et al., 2003; Garami et al., 2003; Inoki et al., 2003a; Tee et al., 2003; Zhang et al., 2003) evidence that Rheb-GTP is a necessary upstream activator of TOR complex 1 signaling, what is Rheb and how does it regulate TOR complex 1? Rheb (NP_005605) is a member of the Ras subfamily of small GTPases (see Colicelli, 2004 for a sequence pileup), first identified as a brain mRNA whose expression is greatly increased after seizure induction (Yamagata et al., 1994) . Rheb expression in hippocampus is increased, in an N-methyl-D-aspartate receptor-dependent manner, by a stimulation protocol that elicits long-term potentiation (LTP), and in cultured cells by exposure to a variety of growth factors. The human Rheb gene (henceforth referred to as Rheb1) is encoded on chromosome 7q36; a second Rheb-like polypeptide (NP_653194, here called Rheb2; also called RhebL1), 52% identical, is encoded on chromosome 12q13.12 (Aspuria and Tamanoi, 2004) ; recombinant Rheb2/RhebL1 also activates mTOR signaling. Interestingly, the Schizosaccharomyces pombe Rheb homolog is approximately 52% identical to Rheb1 and 44% identical to Rheb2. The next most similar human small GTPases are Rap1 and Rap2 (approximately 35% identical to Rheb1/2) and Ras (approximately 32/29% identity with Rheb1/2, respectively). A unique feature of the Rheb sequence is the presence of an arginine at residue15 (equivalent to Ras Gly 12) in the P-loop; substitution of Arg at this site in Ras greatly diminishes GAP-stimulated Ras GTPase activity and yields a transforming Ras protein. As with RasG12R, Rheb R15G is partially resistant to the TSC GAP activity, an inversion that reflects the distinct molecular mechanism of the TSC GAP reaction as compared with Ras-GAPs (Li et al., 2004) . Basal levels of Rheb GTP charging in cultured cells are reported in the range of 15-25%, much higher than those of Ras (B5% in most cells); moreover, modest overexpression of Rheb is accompanied by a rapid increase in fractional GTP content, consistent with the presence of a limiting level of Rheb GAP activity (Im et al., 2002) . The very high extent of Rheb GTP charging in TSC2 null cells (>95%) (Smith et al., 2005; Roccio et al., 2006) suggests that Rheb GAPs apart from the TSC complex may not exist; moreover, a guanyl nucleotide exchange factor acting on Rheb has not yet been identified. Rheb1 is farnesylated, and is localized primarily to intracellular membranes (Takahashi et al., 2005) .
With regard to Rheb functions, early studies demonstrated the ability of Rheb to bind to the Ras-binding domain of c-Raf1, and more recently to BRaf (Im et al., 2002; Karbowniczek et al., 2004) , consistent with the highly conserved sequence of the switch 1 loops of Ras and Rheb (Ras:YDPTIEDSY vs Rheb1/2:YDPTI/ VENTF/Y). Nevertheless, recombinant Rheb only inhibits activation of BRaf, Ras activation of downstream targets such as MAPK and elk1 and vRas transformation of NIH3T3 cells. This is likely to reflect the ability of Rheb when overexpressed to interact with certain Ras-binding domains in a non-productive manner, as occurs with recombinant Rap1. Nevertheless, negative regulation of BRaf by Rheb under physiologic or pathologic (e.g., TSC deficiency) conditions in mammalian cells has been reported, suggesting that BRaf may be a true target (Karbowniczek et al., 2004) . A physiologic view of Rheb function is provided by the knockout of the Rheb in S. cerevisiae or S. pombe. Deletion of ScRheb causes increased susceptibility to the toxic arginine analog, canavanine, apparently owing to upregulated uptake, a phenotype entirely distinct from that of Ras deficiency; S.cerevisiae, however, lacks a TSC homolog, and deletion of ScRheb does not cause the inhibition of cell growth seen with TOR deficiency (Aspuria and Tamanoi, 2004) . In contrast, S. pombe does encode TSC homologs that act on Rheb (van Slegtenhorst et al., 2004) and SpRheb is essential for cell growth in addition to its effects on amino-acid uptake (Yang et al., 2001; Aspuria and Tamanoi, 2004) . Thus, the canavanine sensitivity observed in farnesylation-deficient S. pombe can be rescued by expression of a mutant Rheb susceptible to geranylation (Yang et al., 2001) . Reciprocally, deficiency of S. pombe TSC results in resistance to canavanine owing to decreased arginine transport; the transport of other nutrients is altered by TSC deficiency as well (van Slegtenhorst et al., 2004) . The mechanism by which Rheb controls nutrient uptake in yeast is as yet unknown.
The ability of Rheb to regulate mTOR signaling in mammalian cells is most dramatically visualized in the setting of amino-acid deprivation, where mTOR signaling to S6K and 4E-BP is completely silenced (Long et al., 2005a, b) . Overexpression of wild-type Rheb in amino-acid-deprived cells restores the phosphorylation of S6K(Thr389) and 4E-BP in a dose-dependent, Rapamycin-inhibitable manner, such that with massive Rheb1 (or Rheb2) overexpression, the phosphorylation of S6K(Thr389) is returned fully to levels seen in cells maintained in replete medium. Rheb does not alter Akt or MAPK in such short-term experiments, nor does rescue of S6K phosphorylation from amino-acid withdrawal occur with overexpression of v12Ras or v12Rap1. Using Rheb rescue of S6K (Thr389P) as an assay for Rheb signaling to mTOR, we carried out a limited mutagenesis of regions of Rheb corresponding to those known to interrupt Ras signaling. Not surprisingly, we found that a variety of mutations in the Rheb P-loop, switch1 and switch 2 segments eliminated the ability of Rheb to rescue S6K. Although mutations in the switch 1 loop did not affect Rheb GTP charging, some mutations, for example, Ser20Asn, Asp60Ile, abolished all guanyl nucleotide binding to Rheb, in vivo and in vitro.
Rheb binds and regulates the kinase activity of TOR complex 1
In considering possible mechanisms by which Rheb signaled to mTOR so as to rescue S6K from amino-acid withdrawal, we entertained two general hypotheses. As with other small GTPases, Rheb could initiate one or more signal-transduction pathways that, for example, by increasing intracellular amino-acid pools from metabolism or protein turnover generated downstream signals, which ultimately activated the mTOR kinase. Alternatively, or in addition, Rheb might act directly on the TOR complex 1 to promote its signaling function, that is, TOR complex 1 could be a direct target of Rheb. One finding suggesting that the latter was plausible was the observation of Gao et al. (2002) that recombinant TOR could co-precipitate recombinant and endogenous Insulin and amino-acid regulation of mTOR signaling and kinase activity J Avruch et al TSC1/2 from Drosophila S2 cells. We were able to reproduce this observation in mammalian cells; either recombinant mTOR or mLST8 is capable of coprecipitating endogenous TSC2. If, as indicated by the Drosophila genetics, the function of TSC in the regulation of TOR is solely to act as a Rheb-GAP, the most likely reason for TSC2 to be physically associated with TOR would be to regulate Rheb at that location. This implies a direct interaction of Rheb with TOR complex 1. In fact, overexpression of Rheb in 293 cells does retrieve endogenous mTOR and raptor; although high-grade Rheb overexpression is required, similar expression of v12Ras or v12Rap1 retrieves very much less mTOR (Long et al., 2005b ). An unexpected finding, however, is that inactive Rheb mutants, including the inactive switch 1 and nucleotide-deficient Rheb variants, Ser20Asn and Asp60Ile, also bound mTOR. In fact, the nucleotide-deficient mutants bound mTOR more avidly than did wild-type Rheb, whereas a Rheb mutant (Gln64Leu), known to be charged preferentially with GTP in vivo, retrieved even less mTOR than did wildtype Rheb. The ability of mTOR to bind equally well or better to nucleotide-deficient Rheb as to wild-type Rheb during transient expression is highly atypical for a putative GTPase-effector interaction. As first shown for Ras (Avruch et al., 1994) , and has proven true for nearly all Ras-like GTPases, bona fide effectors, for example, Raf, bind with much higher affinity to the GTP-charged form of the GTPase than to the GDP-charged form. Moreover, the physical interaction of Ras-like GTPases with effectors consistently involves the switch 1 loop of the small GTPase, and functionally inactivating mutations in this segment are nearly always accompanied by loss of binding. In our limited mutagenesis, we did observe that Rheb(Ile39Lys) retrieved consistently lower amounts of mTOR than wild-type Rheb, but the interaction of mTOR with another inactive mutant Rheb(Thr38Met) was similar to wild type. Concerned about the technical validity of the Rheb-mTOR interaction observed using transient expression, we compared directly the ability of purified recombinant Rheb and v12Ha-Ras, each charged in vitro with GTP or GDP, to bind to an amino-terminal fragment of c-Raf1 encompassing the Ras-binding domain (RBD). Whereas Ras-GTP bound to the c-Raf1 amino-terminal polypeptide with much higher affinity than Ras-GDP, Rheb, although exhibiting specific binding to this c-Raf1 fragment, bound to a comparable extent whether charged with GTP or GDP (Long et al., 2005b) . This side-by-side comparison persuaded us that the relative indifference of the Rheb-RBD interaction to whether Rheb was charged with GTP or GDP, although uncharacteristic of the behavior of Ras-like GTPases, was not owing to technical factors, but accurately reflected the manner in which Rheb interacted with a bona fide Ras binding domain. In view of the atypical properties of the Rheb-TOR interaction, it was imperative to gain some evidence as to whether Rheb binding to mTOR had any functional significance for mTOR signaling or for the regulation of the mTOR kinase activity. This raised the question as to the molecular mechanism by which insulin or amino acids regulate TOR complex 1 kinase activity. Several groups have reported that insulin or serum treatment of cultured cells can promote an increase in mTOR kinase activity assayed in immunoprecipitates, with maximal reported stimulations of about twofold (Scott et al., 1998; Sekulic et al., 2000) . We have been unable to reliably detect insulin-induced increases in mTOR kinase toward 4E-BP of more than 30-50% and are uncertain as to whether such effects reflect the extent or mechanism of mTOR regulation occurring in vivo. The situation is even more clearcut with regard to aminoacid/leucine withdrawal; whereas TOR complex 1 signaling in vivo is inhibited completely by these maneuvers, the kinase activity of mTOR extracted from amino-acid-deficient or -replete cells, assayed in vitro, is indistinguishable (Hara et al., 1998) . This behavior led us to conclude that at least for leucine/amino acids, and perhaps for insulin, the regulation of mTOR kinase activity in vivo is accomplished predominantly by noncovalent interactions which are lost on cell disruption, rather than by the introduction of stable post-translational modifications into the components of TOR complex 1. Consistent with this earlier experience, we observed that transfection of Rheb, in amounts sufficient to fully restore S6K activity from amino-acid withdrawal, with mTOR (with or without additional transfection of raptor and mLST8) did not alter mTOR kinase activity assayed in vitro, whether extracted from amino-acid-deficient or -replete cells, the latter with or without treatment with insulin or serum before extraction. Moreover, addition in vitro of purified recombinant Rheb-GTP or Rheb-GDP to mTOR immunoprecipitates did not alter the kinase activity of recombinant or endogenous mTOR, regardless of whether mTOR was extracted from amino-acid-replete or -deficient cells.
Seeking an alternative strategy, we focused on the ability of both recombinant wild-type and mutant inactive Rheb to bind endogenous and recombinant mTOR. Although the amount of endogenous mTOR recovered with recombinant Rheb was sufficient for detection of the kinase activity, it was possible to substantially increase the Rheb-associated mTOR polypeptide and S6K (Thr389) and 4E-BP kinase activity by coexpression of mTOR with Rheb. We therefore examined the kinase activity of mTOR retrieved with wild-type Rheb (whose fractional GTP charging was measured at 50-60%), side-by-side with mTOR bound to the inactive, nucleotide-deficient Rheb mutants Ser20Asn and Asp60Ile, and to Rheb (Gln64Leu), a mutant whose fractional GTP charging is near 90% (Li et al., 2004) . Equalizing the amounts of mTOR polypeptide introduced into the kinase assays, the results proved clearcut; whereas the mTOR co-precipitating with wild-type Rheb had reproducible kinase activity toward S6K (Thr389) and 4E-BP, an equal amount of mTOR polypeptide bound to the nucleotidedeficient Rheb mutants had less than 10% the kinase activity toward either substrate, approaching the lower detection limit of our kinase assays. The small amount of mTOR bound to v12Ha-Ras was also essentially devoid of kinase activity when compared with an equal amount of mTOR bound to wild-type Rheb. Reciprocally, the mTOR bound to Rheb(Gln64Leu) exhibited approximately twice the kinase-specific activity as mTOR bound to wild-type Rheb; although indirect, this result indicates that Rheb-GDP does not support activation of the mTOR kinase.
These results provide very strong evidence that the binding of Rheb to mTOR is related to the ability of Rheb to regulate the mTOR kinase activity, and thus mTOR signaling in vivo. Moreover, they unveil a new mode of action of a Ras-like GTPase, wherein GTP charging does not control primarily the binding of the GTPase to the effector target, but rather controls the activation of the effector. Additional evidence for a regulatory direct interaction between Rheb and TOR comes from work in S. pombe, where a screen for hyperactive Rheb mutants recovered at least one that exhibits a markedly greater binding to TOR in vivo than the wild-type Rheb (Urano et al., 2005) . Interestingly, this mutant appears to be selectively deficient in the ability to bind GDP; whether its enhanced binding to SpTOR is attributable to a possible increased fractional GTP charging or is a parallel but independent outcome of the mutation was not resolved, and is an issue we are investigating using mammalian Rheb. We remain open to the possibility that at physiologic concentrations in vivo, the Rheb-mTOR interaction is GTP dependent; the apparent GTP-independence we observe may be attributable to the massive overexpression of Rheb employed, such that the action of an as yet unidentified element that promotes the GTP-dependent binding is obscured. Activation of mTOR kinase by Rheb does require an intact Rheb switch 1 loop, implying that this region of Rheb is likely to contact mTOR in a GTPregulated manner; nevertheless, the Rheb switch 1 loop does not contribute energetically in a major way to the Rheb/mTOR interaction in vivo or in vitro; this interaction is presumably mediated by Rheb segments whose configuration is largely unaffected by GTP/GDP cycling. The role of Ras-GTP in the regulation of the Type 1A/B PI-3 kinases is analogous to Rheb in some respects. Unlike the Ras-Raf interaction, Ras-GTP does not control membrane recruitment of the Type 1 PI-3 kinase complex, which is mediated by the PI-3 kinase p85 or p101 subunits; once the PI-3 kinase p110 catalytic subunit is at the membrane, the low-affinity (although still GTP dependent) association with Ras serves primarily to amplify the p110 catalytic activity (Rodriguez-Viciana, 1996) . Despite the apparently low affinity of Rheb binding to mTOR, both polypeptides are largely or entirely associated with endomembranes Wedaman et al., 2003; Drenan et al., 2004; Takahashi et al., 2005) , so that their interaction in vivo depends, at worst, on diffusion in only two dimensions. The finding that nucleotide-deficient Rheb mutants bind to TOR more tightly than wild-type Rheb, and block mTOR from adopting an active configuration is reminiscent of the behavior of Rap1-GTP toward cRaf1; Rap1-GTP binds to c-Raf1 more tightly than does Ras-GTP, but actually inhibits the ability of c-Raf1 to achieve activation (Hu et al., 1995) .
Once confident of the regulatory significance of the Rheb-mTOR interaction, we mapped the Rheb binding site on mTOR, localizing it to mTOR amino acids 2148-2300 (Long et al., 2005b) . This corresponds to the amino-terminal small lobe of the mTOR catalytic domain, including the probable ATP binding site, which, based on homology to the PI-3 kinase-a, includes the universally conserved Lys at mTOR (2187) and the glycine-rich sequence GLIGW (2238). This region is well conserved within the PIKK family, leading us to inquire whether Rheb can bind to other members, such as ATM or ATR. The homologous carboxy-terminal segments mTOR (2148-2549), ATM (2678-3056) and ATR (2288-2644) each exhibited specific and comparable binding to coexpressed Rheb; in contrast, Rheb did not bind to the catalytic domains of any of the several conventional protein kinases tested. The functional significance of the Rheb binding to ATM/ATR is currently under study.
Inasmuch as mTOR phosphorylates S6K and 4E-BP in an obligatory complex with raptor and LST8, we also inquired whether Rheb can interact with these polypeptides. Using transient expression, wild-type and mutant Rheb co-precipitate both mLST8 and raptor, especially the raptor carboxy-terminal WD propellor domain. Binding reactions carried out in vitro with purified polypeptides verified the ability of Rheb to bind directly and specifically to the mTOR catalytic domain, mLST8 and the raptor carboxy-terminal WD domain, in a manner largely independent of the identity of the bound guanyl nucleotide; in contrast, parallel reactions showed that the TSC2 GAP domain binds Rheb-GTP with substantial preference over Rheb-GDP. Evidence is currently lacking as to the functional significance of Rheb binding to mLST8 and raptor, inasmuch as the effective folding of these seven-leaved WD propellors when overexpressed is challenging, and therefore they are potentially 'sticky' polypeptides. Nevertheless, raptor has already been shown to bind simultaneously to the substrates S6K/4E-BP and mTOR, and displacement of raptor from the mTOR complex, whether by detergent in vitro, or by the FKBP12/Rapamycin complex in vivo, markedly inhibits mTOR catalysed substrate phosphorylation. Thus, it would be premature to disregard the possibility of a functional role for a Rheb/raptor interaction. These WD propellors are homologous in structure to the b-subunits of the heterotrimeric GTPases (Smith et al., 1999; Liu et al., 2001) . It is well known that the b/g-heterodimer, utilizing several surfaces, is capable of interaction with and functional regulation of multiple partners (Gautam et al., 1998; Mirshahi et al., 2002) . Whether LST8 is capable of multiple independent regulatory interactions is not known. The site of LST8 binding on mTOR was previously mapped to amino acids 2115-2431 (Kim et al., 2002) , overlapping the segment that binds Rheb; however, Rheb does not bind to mTOR through LST8. Although LST8 binds mTOR much more tightly than does Rheb, we find no evidence that the binding of Rheb and LST8 to mTOR is either competitive or cooperative; thus, Rheb binds to mTOR independent of, but adjacent to LST8. In contrast to the effects of Rheb on mTOR kinase, overexpression of LST8 stimulates the kinase activity of mTOR assayed in vitro several fold (four-to fivefold in our experiments), but does not rescue S6K (Thr389) phosphorylation from amino-acid deprivation in vivo (Kim et al., 2002) . Thus, Rheb and LST8 bind to each other and also to the mTOR catalytic domain, and each regulates mTOR, but in a differential manner.
Amino-acid sufficiency regulates the Rheb-mTOR interaction in vivo
In the course of characterizing the binding of Rheb to mTOR, we observed that the interaction was unaffected by treatment of cells with insulin, wortmannin/ Ly294002 or Rapamycin before extraction. Conversely, the retrieval of full-length mTOR with Rheb was greatly diminished by a 2 h withdrawal of medium amino acids, and equally inhibited by removal of only leucine or arginine (Long et al., 2005b) , as is mTOR signaling. The inhibitory effect of amino-acid withdrawal on the RhebmTOR interaction was also evident on the binding of Rheb to mTOR carboxy-terminal fragment (2148-2549), whereas the recovery of the raptor carboxyterminal WD propellor domain and LST8 with Rheb was unaffected by amino-acid withdrawal. The inhibitory effect of amino-acid withdrawal on the Rheb/ mTOR interaction is not owing to changes in Rheb GTP charging; a 2-h amino-acid withdrawal does not alter the fractional GTP charging of recombinant Rheb. Moreover, the binding of mTOR to the nucleotide-deficient Rheb mutants is inhibited by amino-acid withdrawal to an extent identical to wild-type Rheb. Rather, the inhibitory effect of amino-acid withdrawal is exerted entirely through an action on mTOR. Deletion of the mTOR (2148-2549) fragment to (2148-2430) removes all sequences distal to the mTO catalytic domain; the binding to Rheb is unaltered, and continues to be inhibited by amino-acid depletion. Deletion of the larger lobe of the mTOR catalytic domain, to yield the mTOR (2148-2300), the minimal Rheb binding fragment, does not diminish the binding of Rheb; however, Rheb binding to this minimal fragment is completely insensitive to prior amino-acid depletion. Thus, it appears that amino-acid/leucine withdrawal, through an action directed at the lower, larger lobe of the mTOR catalytic domain, interferes with the ability of the upper lobe to bind in vivo to Rheb. The biochemical basis for this action is unknown; it does not appear to be owing to a stable post-translational modification of mTOR, inasmuch as the mTOR (2148-2549) fragment, whether extracted form amino-acid-replete or -deprived cells, binds similarly in vitro to Rheb, whether the latter is charged with GTP, GDP or free of nucleotide. Whether leucine provides a positive signal that promotes the binding of Rheb to mTOR, or leucine withdrawal generates an inhibitory moiety that binds to the mTOR lower lobe and interferes with Rheb binding to the adjacent upper lobe (and perhaps also inhibits mTOR kinase activity in vivo), is unknown. In either event, the effect of the amino-acid-dependent factor is lost upon cell disruption.
The findings suggest a simple model for the ability of recombinant Rheb to rescue TOR complex 1 from inhibition by amino-acid withdrawal (Figure 1) . Thus, amino-acid withdrawal deactivates the TOR complex 1 by interfering with the binding of Rheb to mTOR and thus the ability of Rheb to configure mTOR into an active kinase. Compatible with this is the ability of amino-acid withdrawal to deactivate mTOR even in TSC2 null cells, wherein endogenous Rheb GTP charging is sustained at >95% despite amino-acid depletion. Massive overexpression of Rheb, which floods the cell with Rheb-GTP polypeptides, is able, simply by mass action, to overcome the diminished association of endogenous Rheb-GTP with mTOR caused by amino-acid withdrawal. Thus, the ability of Rheb to bind directly to TOR complex 1 and, when GTP charged, to enable mTOR configuration into an active kinase, accounts for the ability of recombinant Rheb to restore the capacity of TOR complex 1 to signal in vivo despite prior depletion of amino acids.
Summary and perspective
It appears that a signal-transduction pathway from the insulin receptor to the p70 S6K can now be described, with each reaction accounted (Figure 2 ). The major discoveries during the prior several years include the identification in Drosophila of the TSC complex and Rheb as components of the pathway upstream of TOR, the regulation of the TSC complex by Akt, the biochemical function of the TSC complex as a Rheb-GAP, the ability of Rheb to bind and directly regulate the kinase activity of mTOR, the operation of mTOR in a complex with LST8 and raptor, the role of raptor as a necessary scaffold for the mTOR catalysed phosphorylation of p70 S6K(Thr389) and 4E-BP, the role of mTOR catalysed phosphorylation in enabling PDK1 to phosphorylate the S6K activation loop and complete S6K activation. Nevertheless, several features of this limb of the signaling pathway downstream of Akt remain to be filled in, and the components that mediate regulation by amino-acid sufficiency are still poorly defined. Thus, considerable evidence indicates that phosphatidic acid, generated by the action of phospholipase D, binds directly to the mTOR FRB domain and is a positive regulator of mTOR signaling (Fang et al., 2001 (Fang et al., , 2003 Kam and Exton, 2004) . More recent evidence suggests that the Type III PI-3 kinase, that is, the vps34 homolog, via generation of PI-3P, is also a positive stimulus that may participate especially in the amino-acid regulation of TOR activity (Byfield et al., 2005; Nobukuni et al., 2005) . The specific site of action of PI-3P in TOR regulation and the identity of the other elements interceding between extracellular amino acids and the Rheb/mTOR interaction is unknown. Many other intriguing questions remain, such as the identity of Rheb targets apart from TOR complex 1, the identity of the mRNAs relevant to cell growth that are regulated downstream of TOR complex 1 and the underlying mechanisms of their regulated expression, the regulation and TOR complex 2 and the identity of its substrates apart from Akt. In the presence of insulin and amino acids, TORC1 substrates, bound to raptor (green), make productive contact with the mTOR catalytic domain (orange). LST8 (pale blue) and Rheb (purple) bind to the upper lobe of the catalytic domain, and Rheb may also contact raptor and LST8; Rheb-GTP binds in a manner that promotes an active configuration of TORC1. A hypothetical, amino-acid-dependent component (yellow) may promote the association of Rheb with TORC1 and perhaps confer preferential association with Rheb-GTP. Lower left: In the absence of insulin, TSC1/2 Rheb-GAP activity is increased, Rheb is predominantly in the GDP-bound state and adopts a conformation that suppresses mTOR kinase activity and/or disallows effective coupling between mTOR and raptor. Lower right: When deprived of amino acids (especially. leucine or arginine), the binding of Rheb to the mTOR catalytic domain is weakened, due either to a decrease in the hypothetical 'activator' component, or alternatively, to the appearance of a hypothetical 'inhibitor' (blue) that by binding to the larger lobe of the mTOR catalytic domain interferes with Rheb binding and/or inhibits mTOR kinase activity.
